

s 2022 0057

The invention relates to medicine, in particular to molecular genetics, gynecology and oncology, and can be used for predicting the course of stage I-II endometrial cancer.

Summary of the invention consists in that it is analyzed the isolated genomic DNA using the chain polymerization reaction, where is determined the presence of c.389G>A (p.R130Q) mutation of the PTEN gene, if its presence is determined, an unfavorable course of endometrial cancer is predicted, and if the presence of mutation is not determined, a favorable course of the disease is predicted.

Claims: 1